about
Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells.Cancer genetics and the cardiotoxicity of the therapeutics.Stem cells and stem cell-derived tissues and their use in safety assessment.Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.A high-throughput screen for teratogens using human pluripotent stem cells.Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.Stem Cell Research.A comparison of 24 chemicals in the six-well bacterial reverse mutation assay to the standard 100-mm Petri plate bacterial reverse mutation assay in two laboratoriesStem cell derived tissues and microphysiological systems: a paradigm shifting momentThalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches
P50
Q35463524-E780F978-52C4-4D7A-8431-31260E68EE47Q38074793-78D7BABC-C1AE-43B0-82EE-FE342C067261Q38173227-075BAB93-567D-463E-AF68-EB81E7F338FEQ38240972-63A92D8C-7EC9-4901-96AD-ADD331040A49Q42708771-113402D4-7D8E-459E-911F-E04C484ADA10Q42709339-6600E66D-5BB8-4758-8063-A1C57781533BQ53222817-6A4A3A01-8A94-45DC-8ED7-1CFDF1F2E7D5Q58550056-416A587E-3F1A-4DE3-9B2D-50D173F6C44AQ86536411-F5E3B21C-FA16-467A-96C7-9FB176C95767Q89767252-FA6032E8-4F05-4439-A519-711B9437E011Q91999150-1727C3D9-D741-4359-8E26-78FAB150C8F3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Kyle L Kolaja
@en
Kyle L Kolaja
@nl
type
label
Kyle L Kolaja
@en
Kyle L Kolaja
@nl
prefLabel
Kyle L Kolaja
@en
Kyle L Kolaja
@nl
P31
P496
0000-0003-1520-9037